IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – What’s Next?

IPSEN (OTCMKTS:IPSEY) saw strong trading volume on Monday . 5,170 shares changed hands during mid-day trading, an increase of 79% from the previous session’s volume of 2,895 shares.The stock last traded at $43.23 and had previously closed at $44.63.

Analyst Upgrades and Downgrades

IPSEY has been the subject of several recent research reports. BNP Paribas Exane downgraded IPSEN to an “underperform” rating in a report on Wednesday, November 26th. UBS Group downgraded shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Tuesday, February 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, IPSEN presently has a consensus rating of “Hold”.

IPSEN Stock Performance

The business has a 50 day moving average price of $43.22 and a 200-day moving average price of $38.00.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).